4th Year MBBS
Neuroscience
Parkinson Disease and Antiparkinsonian Pharmacotherapy
Connect the pathology, clinical manifestations and major drug actions into one rapid-revision framework.
1. THE TOPIC IN ONE CONNECTED FLOW
Parkinson disease begins with progressive degeneration of dopaminergic neurons in the substantia nigra. The resulting fall in striatal dopamine disturbs basal ganglia control of movement, producing characteristic motor features. Treatment improves function by increasing dopamine availability, directly stimulating dopamine receptors or reducing dopamine breakdown, but long-term dopaminergic therapy may itself produce important motor fluctuations.
2. KEY CLINICAL CONNECTIONS
Loss of pigmented nigral neurons → striatal dopamine falls → movement initiation and amplitude decrease → bradykinesia, micrographia, masked facies and hypophonia.
Levodopa crosses the blood-brain barrier → converted to dopamine → improves bradykinesia and rigidity. Carbidopa or benserazide reduces peripheral conversion → more levodopa reaches the CNS and peripheral adverse effects decrease.
D2-receptor blockade or dopamine depletion → reduced basal ganglia dopaminergic signaling → bilateral Parkinsonian features → reduce or remove the causative drug; antimuscarinic therapy or amantadine may help troublesome symptoms.